Iopromide
Based on 2 publication(s) in Google Scholar
Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.03%
- No. CAS: 73334-07-3
- Fòrmula: C18H24I3N3O8
- Peso molecular:791.11
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Iopromide
More
Actividad biológica
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 73334-07-3
-
Appearance Solid
-
Peso molecular 791.11
-
Fòrmula C18H24I3N3O8
-
Color White to off-white
-
SMILES
O=C(C1=C(I)C(NC(COC)=O)=C(I)C(C(NCC(O)CO)=O)=C1I)N(CC(O)CO)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. [Abstract]2024 Nov 9;43(11):114962. PMID: 39522165 -
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299
Solvente y solubilidad
H2O : 100 mg/mL (126.40 mM; Need ultrasonic)
DMSO : 100 mg/mL (126.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (126.40 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocolo
Mice: Male C57/BL6J mice are randomly divided into 7 groups: control, diabetes mellitus (D), CIN, diabetes mellitus+CIN (DC), diabetes mellitus+Breviscapine (DB), CIN+Breviscapine (CIN+B) and diabetes mellitus+CIN+Breviscapine (DCB). After the model of diabetes mellitus is established, mice are prohibited drinking water for one night, and then mice are injected at a dose of 10 mL/kg iopromide via tail vein administration over the course of 1 minute. Then the mice are treated intragastrically with or without Breviscapine (10 mg/kg/d) for 4 weeks. Other mice groups except for Breviscapine treatment groups (DB, DCB and CIN+B) are administered the same volume of phosphate buffered solution intragastrically for 4 weeks. Then mice are sacrificed by an intraperitoneal injection of chloral hydrate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (459 KB)
- English - EN (459 KB)
- Français - FR (459 KB)
- Deutsch - DE (459 KB)
- Norwegian - NO (459 KB)
- Español - ES (459 KB)
- Swedish - SV (459 KB)
- Italian - IT (459 KB)
- Korean - KR (459 KB)
- Portuguese - PT (459 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Jiang W, et al. Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice. Am J Transl Res. 2016 Feb 15;8(2):329-41. [Content Brief]
[2]. McCormack PL, et al. Iobitridol: a review of its use as a contrast medium in diagnostic imaging. Clin Drug Investig. 2013 Feb;33(2):155-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.2640 mL | 6.3202 mL | 12.6405 mL | 31.6012 mL |
| 5 mM | 0.2528 mL | 1.2640 mL | 2.5281 mL | 6.3202 mL | |
| 10 mM | 0.1264 mL | 0.6320 mL | 1.2640 mL | 3.1601 mL | |
| 15 mM | 0.0843 mL | 0.4213 mL | 0.8427 mL | 2.1067 mL | |
| 20 mM | 0.0632 mL | 0.3160 mL | 0.6320 mL | 1.5801 mL | |
| 25 mM | 0.0506 mL | 0.2528 mL | 0.5056 mL | 1.2640 mL | |
| 30 mM | 0.0421 mL | 0.2107 mL | 0.4213 mL | 1.0534 mL | |
| 40 mM | 0.0316 mL | 0.1580 mL | 0.3160 mL | 0.7900 mL | |
| 50 mM | 0.0253 mL | 0.1264 mL | 0.2528 mL | 0.6320 mL | |
| 60 mM | 0.0211 mL | 0.1053 mL | 0.2107 mL | 0.5267 mL | |
| 80 mM | 0.0158 mL | 0.0790 mL | 0.1580 mL | 0.3950 mL | |
| 100 mM | 0.0126 mL | 0.0632 mL | 0.1264 mL | 0.3160 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Iopromide Related Classifications
HY-B1362 Related Classifications
Powered by Bioz